YL
Therapeutic Areas
Beyond Air Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LungFit PH | Persistent Pulmonary Hypertension of the Newborn (PPHN) | Approved |
| LungFit PRO | Viral Community-Acquired Pneumonia (VCAP), including COVID-19 | Pilot |
| LungFit GO | Nontuberculous Mycobacteria (NTM) Lung Infection | Pilot |
| UNO (Ultrahigh NO) | Cutaneous / Near Cutaneous Tumors | Phase 1 |
| BA-102 (nNOS Inhibitor) | Autism Spectrum Disorder / Phelan-McDermid Syndrome | Preclinical |
| BA-101 (nNOS Inhibitor) | Early Onset Alzheimer's Disease | Preclinical |
Leadership Team at Beyond Air
RG
Robert Goodman
CEO and Board Director
DM
Dan Moorhead
Chief Financial Officer
FM
Frederick Montgomery
Vice President, Medical Systems
MG
Michael Gaul
Chief Operating Officer
JJ
John Jett
Head of Research and Clinical Development
RF
Robert F. Carey
Chairman of the Board
EL
Erick Lucera
Director
BF
Bill Forbes
Director